Similarly, an earlier report demonstrating drug resistance against EGFR therapy in rectal diseases and non-small cell lung cancer through dysregulation of EGFR endocytosis can be explained via identified off-targets (LYN, SRC, ABL2, ABL1, SYK, TNK2, MAPKAPK2, GAK and MAPK1) that are involved in endocytosis process. This evidence concerns the gene ABL1 and non-small cell lung carcinoma.